Inside Innovation

Investment into the Seattle biotech scene continues as Lumen Bioscience announced it received $16 million in Series B funding. The startup, led by former Adaptive

Athira Pharma, which develops therapies for brain diseases such as Alzheimer’s and Parkinson’s, filed for an IPO last week. Athira’s regenerative technology works to rebuild

Nanodropper, a medical device startup launched by a group of University of Washington students, announced that it received $500,000 in funding from the United States

Amid an economic downturn, Washington state’s life science industry is growing and hiring for hundreds of open positions at all levels. To fuel this expansion,

Bristol Myers Squibb announced that it will commit $300 million over the next five years to tackle racial health disparities and accelerate its diversity and

Life Science Washington announced the launch of its new campaign, “Find Your Best Life in Washington,” to encourage top talent nationwide to learn more about

Chinook Therapeutics, a Vancouver, B.C. based company with offices in Seattle, raised $106 million in advance of an upcoming reverse merger with Berkeley, California-based Aduro

Seattle-based Sana Biotechnology and Silverback Therapeutics are among the 21 biotech startups that 12 top biotech venture capital investors are eyeing for investment opportunities in

Microsoft and its Seattle-based neighbor Adaptive Biotechnologies have been in partnership since 2018 on immuno-sequencing advancements. Now, they’re pivoting their work to collaborate on COVID-19

Adaptive Biotechnologies received FDA clearance for the clonoSEQ® Assay, used to assess the minimal residual disease in a chronic lymphocytic leukemia patient’s blood. Previously, the

Boston-based biotech startup GentiBio has secured licensing deals with Seattle Children’s Research Institute and Benaroya Research Institute at Virginia Mason. The technology from both Seattle-based

Adaptive Biotechnologies is continuing with its plans to move into a 100,000-square-foot headquarters. The new facility, slated to open next year, will allow Adaptive to